Neurotrope, Inc. reported that Dr. Warren Wasiewski, Executive Vice President, Development and Chief Medical Officer of Neurotrope Bioscience, Inc., a wholly-owned subsidiary of Neurotrope, Inc., has resigned as Executive Vice President, Development, effective as of November 9, 2015 and has taken a new position with significantly more responsibility. Dr. Wasiewski will remain Acting Chief Medical Officer of Neurotrope Bioscience Inc., on a consulting basis, until the earlier of December 31, 2015 or the date that a successor is named. Dr. Wasiewski was responsible for development of the Company's planned Phase 2b clinical trial to treat approximately 150 patients with bryostatin who suffer with moderately severe to severe Alzheimer's disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.55 USD | +2.48% | +0.89% | -33.06% |
May. 15 | Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 09 | Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. | CI |
1st Jan change | Capi. | |
---|---|---|
-33.06% | 4.94M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- SNPX Stock
- News Synaptogenix, Inc.
- Neurotrope Bioscience, Inc. Announces Resignation of Warren Wasiewski as Executive Vice President, Development